Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC)
暂无分享,去创建一个
B. Wiedenmann | M. Pavel | F. Neumann | U. Pape | C. Bartel | U. Plöckinger | F. Heuck | N. Tiling